Header Logo

Connection

Diego Cadavid to Humans

Back to Details
This is a "connection" page, showing publications Diego Cadavid has written about Humans.
Diego Cadavid
Connection Strength
0.604
Humans
  1. Jalnapurkar I, Frazier JA, Roth M, Cochran DM, Foley A, Merk T, Venuti L, Ronco L, Raines S, Cadavid D. The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study. J Neurodev Disord. 2022 12 09; 14(1):57.
    View in: PubMed
    Score: 0.032
  2. Mellion ML, Widholm P, Karlsson M, Ahlgren A, Tawil R, Wagner KR, Statland JM, Wang L, Shieh PB, van Engelen BGM, Kools J, Ronco L, Odueyungbo A, Jiang J, Han JJ, Hatch M, Towles J, Leinhard OD, Cadavid D. Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis. Neurology. 2022 08 30; 99(9):e877-e889.
    View in: PubMed
    Score: 0.031
  3. Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulovic J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 09; 18(9):845-856.
    View in: PubMed
    Score: 0.026
  4. Petrillo J, Balcer L, Galetta S, Chai Y, Xu L, Cadavid D. Initial Impairment and Recovery of Vision-Related Functioning in Participants With Acute Optic Neuritis From the RENEW Trial of Opicinumab. J Neuroophthalmol. 2019 06; 39(2):153-160.
    View in: PubMed
    Score: 0.025
  5. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H, Ziemssen F, Massacesi L, Chai Y, Xu L, Freeman S. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar; 16(3):189-199.
    View in: PubMed
    Score: 0.022
  6. Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Antibiotics for the neurological complications of Lyme disease. Cochrane Database Syst Rev. 2016 12 08; 12:CD006978.
    View in: PubMed
    Score: 0.021
  7. Goldman MD, Ward MD, Motl RW, Jones DE, Pula JH, Cadavid D. Identification and validation of clinically meaningful benchmarks in the 12-item Multiple Sclerosis Walking Scale. Mult Scler. 2017 Sep; 23(10):1405-1414.
    View in: PubMed
    Score: 0.021
  8. Cadavid D, Cohen JA, Freedman MS, Goldman MD, Hartung HP, Havrdova E, Jeffery D, Kapoor R, Miller A, Sellebjerg F, Kinch D, Lee S, Shang S, Mikol D. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Mult Scler. 2017 01; 23(1):94-105.
    View in: PubMed
    Score: 0.021
  9. Motl RW, Putzki N, Pilutti LA, Cadavid D. Longitudinal changes in self-reported walking ability in multiple sclerosis. PLoS One. 2015; 10(5):e0125002.
    View in: PubMed
    Score: 0.019
  10. Goldman MD, Motl RW, Scagnelli J, Pula JH, Sosnoff JJ, Cadavid D. Clinically meaningful performance benchmarks in MS: timed 25-foot walk and the real world. Neurology. 2013 Nov 19; 81(21):1856-63.
    View in: PubMed
    Score: 0.017
  11. Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013 Jul; 27(7):493-503.
    View in: PubMed
    Score: 0.017
  12. Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013 Apr 25; 13:37.
    View in: PubMed
    Score: 0.017
  13. Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One. 2013; 8(1):e53297.
    View in: PubMed
    Score: 0.016
  14. Orbach R, Zhao Z, Wang YC, O'Neill G, Cadavid D. Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials. PLoS One. 2012; 7(10):e45409.
    View in: PubMed
    Score: 0.016
  15. Johnson MA, Cadavid D. Simvastatin in acute optic neuritis. Mult Scler. 2012 Nov; 18(11):1657; author reply 1658.
    View in: PubMed
    Score: 0.016
  16. Cheriyan J, Kim S, Wolansky LJ, Cook SD, Cadavid D. Impact of inflammation on brain volume in multiple sclerosis. Arch Neurol. 2012 Jan; 69(1):82-8.
    View in: PubMed
    Score: 0.015
  17. Cadavid D, Kim S, Peng B, Skurnick J, Younes M, Hill J, Wolansky LJ, Cook SD. Clinical consequences of MRI activity in treated multiple sclerosis. Mult Scler. 2011 Sep; 17(9):1113-21.
    View in: PubMed
    Score: 0.015
  18. Londo?o D, Carvajal J, Strle K, Kim KS, Cadavid D. IL-10 Prevents apoptosis of brain endothelium during bacteremia. J Immunol. 2011 Jun 15; 186(12):7176-86.
    View in: PubMed
    Score: 0.015
  19. Tumani H, Cadavid D. Are high CSF levels of CXCL13 helpful for diagnosis of Lyme neuroborreliosis? Neurology. 2011 Mar 22; 76(12):1034-5.
    View in: PubMed
    Score: 0.014
  20. Cadavid D, Tang Y, O'Neill G. [Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis]. Rev Neurol. 2010 Sep 16; 51(6):321-9.
    View in: PubMed
    Score: 0.014
  21. Cadavid D. Spirochetal infections. Handb Clin Neurol. 2010; 96:179-219.
    View in: PubMed
    Score: 0.013
  22. Festa ED, Hankiewicz K, Kim S, Skurnick J, Wolansky LJ, Cook SD, Cadavid D. Serum levels of CXCL13 are elevated in active multiple sclerosis. Mult Scler. 2009 Nov; 15(11):1271-9.
    View in: PubMed
    Score: 0.013
  23. Cadavid D, Garcia E, Gelderblom H. Coinfection with Borrelia turicatae serotype 2 prevents the severe vestibular dysfunction and earlier mortality caused by serotype 1. J Infect Dis. 2007 Jun 01; 195(11):1686-93.
    View in: PubMed
    Score: 0.011
  24. Sethi N, Sondey M, Bai Y, Kim KS, Cadavid D. Interaction of a neurotropic strain of Borrelia turicatae with the cerebral microcirculation system. Infect Immun. 2006 Nov; 74(11):6408-18.
    View in: PubMed
    Score: 0.010
  25. Wolansky LJ, Haghighi MH, Sevdalis E, Cook SD, Sethi N, Liu J, Joseph G, Tulloch K, Cadavid D. Safety of serial monthly administration of triple-dose gadopentetate dimeglumine in multiple sclerosis patients: preliminary results of the BECOME trial. J Neuroimaging. 2005 Jul; 15(3):289-90.
    View in: PubMed
    Score: 0.010
  26. Pachner AR, Dail D, Bai Y, Sondey M, Pak L, Narayan K, Cadavid D. Genotype determines phenotype in experimental Lyme borreliosis. Ann Neurol. 2004 Sep; 56(3):361-70.
    View in: PubMed
    Score: 0.009
  27. Tawil R, Wagner KR, Hamel JI, Leung DG, Statland JM, Wang LH, Genge A, Sacconi S, Lochm?ller H, Reyes-Leiva D, Diaz-Manera J, Alonso-Perez J, Muelas N, Vilchez JJ, Pestronk A, Gibson S, Goyal NA, Hayward LJ, Johnson N, LoRusso S, Freimer M, Shieh PB, Subramony SH, van Engelen B, Kools J, Leinhard OD, Widholm P, Morabito C, Moxham CM, Cadavid D, Mellion ML, Odueyungbo A, Tracewell WG, Accorsi A, Ronco L, Gould RJ, Shoskes J, Rojas LA, Jiang JG. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2024 May; 23(5):477-486.
    View in: PubMed
    Score: 0.009
  28. Cadavid D, Bai Y, Dail D, Hurd M, Narayan K, Hodzic E, Barthold SW, Pachner AR. Infection and inflammation in skeletal muscle from nonhuman primates infected with different genospecies of the Lyme disease spirochete Borrelia burgdorferi. Infect Immun. 2003 Dec; 71(12):7087-98.
    View in: PubMed
    Score: 0.009
  29. Widholm P, Ahlgren A, Karlsson M, Romu T, Tawil R, Wagner KR, Statland JM, Wang LH, Shieh PB, van Engelen BGM, Cadavid D, Ronco L, Odueyungbo AO, Jiang JG, Mellion ML, Dahlqvist Leinhard O. Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability. Muscle Nerve. 2022 08; 66(2):183-192.
    View in: PubMed
    Score: 0.008
  30. Shaffer R, Thurman AJ, Ronco L, Cadavid D, Raines S, Kim SH. Social communication in fragile X syndrome: pilot examination of the Brief Observation of Social Communication Change (BOSCC). J Neurodev Disord. 2022 01 08; 14(1):4.
    View in: PubMed
    Score: 0.008
  31. Mellion ML, Ronco L, Berends CL, Pagan L, Brooks S, van Esdonk MJ, van Brummelen EMJ, Odueyungbo A, Thompson LA, Hage M, Badrising UA, Raines S, Tracewell WG, van Engelen B, Cadavid D, Groeneveld GJ. Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. Br J Clin Pharmacol. 2021 12; 87(12):4658-4669.
    View in: PubMed
    Score: 0.007
  32. DeBevits JJ, Munbodh R, Bageac D, Wu R, DiCamillo PA, Hu C, Wang L, Naismith RT, Karimeddini D, Dhib-Jalbut S, Redko S, Cook SD, Cadavid D, Wolansky L. Gray Matter Nucleus Hyperintensity After Monthly Triple-Dose Gadopentetate Dimeglumine With Long-term Magnetic Resonance Imaging. Invest Radiol. 2020 10; 55(10):629-635.
    View in: PubMed
    Score: 0.007
  33. Rojas LA, Valentine E, Accorsi A, Maglio J, Shen N, Robertson A, Kazmirski S, Rahl P, Tawil R, Cadavid D, Thompson LA, Ronco L, Chang AN, Cacace AM, Wallace O. p38a Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy. J Pharmacol Exp Ther. 2020 09; 374(3):489-498.
    View in: PubMed
    Score: 0.007
  34. Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, Cadavid D, Balcer LJ. Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis. J Neuroophthalmol. 2018 12; 38(4):451-458.
    View in: PubMed
    Score: 0.006
  35. Klistorner A, Chai Y, Leocani L, Albrecht P, Aktas O, Butzkueven H, Ziemssen T, Ziemssen F, Frederiksen J, Xu L, Cadavid D. Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs. 2018 12; 32(12):1159-1171.
    View in: PubMed
    Score: 0.006
  36. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdov? EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 05; 17(5):405-415.
    View in: PubMed
    Score: 0.006
  37. Fern?ndez R, Cardona JA, Cadavid D, ?lvarez LG, Restrepo FA. Survival of Endodontically Treated Roots/Teeth Based on Periapical Health and Retention: A 10-year Retrospective Cohort Study. J Endod. 2017 Dec; 43(12):2001-2008.
    View in: PubMed
    Score: 0.006
  38. Maranzano J, Rudko DA, Nakamura K, Cook S, Cadavid D, Wolansky L, Arnold DL, Narayanan S. MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis. Neurology. 2017 Aug 15; 89(7):714-721.
    View in: PubMed
    Score: 0.006
  39. Brown RA, Narayanan S, Stikov N, Cook S, Cadavid D, Wolansky L, Arnold DL. MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon ?-1b. Neurology. 2016 Aug 30; 87(9):905-11.
    View in: PubMed
    Score: 0.005
  40. Wolansky LJ, Cadavid D, Punia V, Kim S, Cheriyan J, Haghighi M, Cook SD. Hypophosphatemia is Associated with the Serial Administration of Triple-Dose Gadolinium to Patients for Brain MRI. J Neuroimaging. 2015 May-Jun; 25(3):379-83.
    View in: PubMed
    Score: 0.005
  41. Magistrale G, Pisani V, Argento O, Incerti CC, Bozzali M, Cadavid D, Caltagirone C, Medori R, DeLuca J, Nocentini U. Validation of the World Health Organization Disability Assessment Schedule II (WHODAS-II) in patients with multiple sclerosis. Mult Scler. 2015 Apr; 21(4):448-56.
    View in: PubMed
    Score: 0.005
  42. Londo?o D, Cadavid D, Drouin EE, Strle K, McHugh G, Aversa JM, Steere AC. Antibodies to endothelial cell growth factor and obliterative microvascular lesions in the synovium of patients with antibiotic-refractory lyme arthritis. Arthritis Rheumatol. 2014 Aug; 66(8):2124-33.
    View in: PubMed
    Score: 0.005
  43. Erlanger DM, Kaushik T, Caruso LS, Benedict RH, Foley FW, Wilken J, Cadavid D, Deluca J. Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial. J Neurol Sci. 2014 May 15; 340(1-2):123-9.
    View in: PubMed
    Score: 0.004
  44. Edwards KR, Goyal J, Plavina T, Czerkowicz J, Goelz S, Ranger A, Cadavid D, Browning JL. Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. PLoS One. 2013; 8(11):e81007.
    View in: PubMed
    Score: 0.004
  45. Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2013 Dec; 19(14):1826-40.
    View in: PubMed
    Score: 0.004
  46. Motl RW, Cadavid D, Sandroff BM, Pilutti LA, Pula JH, Benedict RH. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores. J Neurol Sci. 2013 Dec 15; 335(1-2):169-73.
    View in: PubMed
    Score: 0.004
  47. Fern?ndez R, Cadavid D, Zapata SM, Alvarez LG, Restrepo FA. Impact of three radiographic methods in the outcome of nonsurgical endodontic treatment: a five-year follow-up. J Endod. 2013 Sep; 39(9):1097-103.
    View in: PubMed
    Score: 0.004
  48. Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012 Nov; 72(5):779-87.
    View in: PubMed
    Score: 0.004
  49. Benedict RH, Smerbeck A, Parikh R, Rodgers J, Cadavid D, Erlanger D. Reliability and equivalence of alternate forms for the Symbol Digit Modalities Test: implications for multiple sclerosis clinical trials. Mult Scler. 2012 Sep; 18(9):1320-5.
    View in: PubMed
    Score: 0.004
  50. Qian P, Cadavid D, Wolansky LJ, Cook SD, Naismith RT. Heterogeneity in longitudinal evolution of ring-enhancing multiple sclerosis lesions. Ann Neurol. 2011 Oct; 70(4):668-9; author reply 669-70.
    View in: PubMed
    Score: 0.004
  51. Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology. 2009 Nov 03; 73(18):1485-92.
    View in: PubMed
    Score: 0.003
  52. Lincoln JA, Cadavid D, Pollard J, McLeod J, Prineas J, Dowling P, Cook SD. We should use magnetic resonance imaging to classify and monitor the course of multiple sclerosis. Arch Neurol. 2009 Mar; 66(3):412-4.
    View in: PubMed
    Score: 0.003
  53. Narayan K, Dail D, Li L, Cadavid D, Amrute S, Fitzgerald-Bocarsly P, Pachner AR. The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. Ann Neurol. 2005 Jun; 57(6):813-23.
    View in: PubMed
    Score: 0.002
  54. Mena H, Cadavid D, Rushing EJ. Human cerebral infarct: a proposed histopathologic classification based on 137 cases. Acta Neuropathol. 2004 Dec; 108(6):524-30.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.